The new CMS initiative dubbed CRUSH aims at cracking down on potentially fraudulent orders for molecular diagnostic tests and ...

Molecular testing, or molecular diagnostics, refers to a group of tests that look at the genetic material in a specimen. It can detect genetic risk factors for certain diseases or provide evidence of ...

As the Centers for Medicare and Medicaid Services calls for public feedback on how to stop lab test fraud, experts say a tailored regulatory strategy will be key to avoid stifling innovation.

Gastrointestinal (GI) infections present a formidable challenge to healthcare systems. As we navigate this landscape, we recognize that there are numerous benefits when moving from conventional to ...

Molecular diagnostics are well-established in clinical medicine. Nonetheless, the markets for these tests remain one of the most attractive growth opportunities in the in vitro diagnostics industry.

December 2024 was declared a "high severity" flu season by the Centre for Disease Control (CDC), the worst in over half a decade. Hospitalization rates were up to 2.8 times higher than the median ...

Faster Test Results for Infection Lead to Safer and More Cost-Effective Hospitals The process of culture-based testing for microbes has been in common use for more than a century. In recent decades, ...

Saliva molecular testing showed strong accuracy for pulmonary tuberculosis. Read more about this nonsputum diagnostic approach.

In oncology care, respiratory can pose serious risks—especially when diagnostic delays disrupt treatment decisions. Yet many clinical labs still rely | Ebooks ...

PARSIPPANY, NJ, July 29, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today responded to the undefined ...

WICHITA, Kan. (KSNW) — As respiratory illnesses continue to surge across the state of Kansas, Wichita State University’s Molecular Diagnostic Lab has announced they are extending free testing through ...

New data supports GraftAssure commercialization effortsMulti-center study featured 249 biopsy-matched patientsProprietary "Combination Model" score outperformed percentage-only measures of dd-cfDNARei ...